Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

["Ephedron" encephalopathy].

O S Levin

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |August 25, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Methcatinone (ephedron) abuse causes brain damage, leading to movement and cognitive disorders. While some symptoms may improve over time, manganese accumulation is a likely cause, and chelation therapy shows limited benefit.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [The potential of a selective anxiolytic afobazole in clinical practice].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Transitional cognitive syndrome: Reconsidered classification of cognitive disorders].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Rapidly progressive cognitive impairment as a single clinical manifestation of anti-NMDA receptor encephalitis].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [New Opportunities in the Treatment of Moderate Cognitive Impairment: Results of the Millennium Study in Real Clinical Practice].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Clinical and kinematic analysis of swimming disorders in Parkinson's disease].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same author

    [Musculoskeletal disorders in patients with Parkinson's disease].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
    Same journal

    [The role of the cerebellum in the coordination of brain activity and the development of autism spectrum disorders].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same journal

    [A clinical case of anxiety-hypochondriacal depression with extensive somatized symptoms in the elderly].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same journal

    [De novo variant in the ATP2B2 gene as a cause of neuropsychiatric developmental disorder].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same journal

    [Electroencephalographic predictors of olfactory stimulus discrimination in COVID-19 survivors].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same journal

    [Effect of long-term carbamazepine therapy on bone metabolism in women with epilepsy].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    Same journal

    [Glial-derived neurotrophic factor and neuropsychological status in COVID-19 survivors].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
    See all related articles

    Area of Science:

    • Neurology
    • Toxicology
    • Radiology

    Background:

    • Methcatinone (ephedron) is a surrogate drug with potential neurotoxic effects.
    • Encephalopathy is a severe brain dysfunction that can result from substance abuse.

    Purpose of the Study:

    • To investigate the clinical, neuropsychological, and MRI findings in patients with methcatinone-induced encephalopathy.
    • To explore the underlying mechanisms and potential treatment strategies for this condition.

    Main Methods:

    • Clinical and neuropsychological assessments using the Scale of clinical assessment of ephedron encephalopathy.
    • Magnetic Resonance Imaging (MRI) to evaluate brain lesions, particularly in the basal ganglia.
    • Correlation analysis to determine relationships between MRI findings, disease duration, and severity.

    Related Experiment Videos

    Main Results:

    • Patients exhibited extrapyramidal disorders, postural instability, pseudobulbar syndrome, and cognitive/affective abnormalities.
    • MRI revealed bilateral symmetric signal abnormalities in the basal ganglia (globus pallidus, substantia nigra) in 86% of patients, suggesting magnesium accumulation.
    • Hyperintensive MRI changes correlated negatively with disease duration but not with drug abuse duration, dosage, or disease severity.
    • Spontaneous symptom regression was observed in 29% of cases, with some improvement noted up to 4 years after cessation of methcatinone intake.

    Conclusions:

    • Methcatinone encephalopathy is characterized by specific neurological and MRI findings.
    • Manganese accumulation in the brain is a probable pathogenic mechanism, potentially leading to mitochondrial dysfunction and oxidative stress.
    • Chelation therapy with EDTA may reduce disease progression but does not significantly improve existing symptoms.
    • Symptomatic treatment for movement and affective disturbances is a key aspect of management.